Your session is about to expire
← Back to Search
Part 1A, Part 1B: GS-1427 Dose C for Ulcerative Colitis (SWIFT Trial)
SWIFT Trial Summary
"This trial is testing a new drug, GS-1427, to see if it is safe and effective in treating people with moderate to severe ulcerative colitis. The study will compare different groups of
SWIFT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SWIFT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the age criterion for participation in this medical study inclusive of individuals who are 65 years or older?
"Eligible participants must be over 18 years old but under the age of 75 to enroll in this study."
Are there any available positions for patients in this ongoing clinical trial?
"Indeed, details on clinicaltrials.gov highlight that this research endeavor is presently enrolling participants. Commencing its public posting on March 27th, 2024, the trial's most recent update was recorded on April 1st of the same year. In total, 423 individuals will be enlisted across six distinct locations for this study."
What is the current number of participants being enrolled in this research project?
"The inclusion criteria mandate the participation of 423 eligible patients in this clinical investigation. Patients have the opportunity to enroll at various sites, including Encore Medical Research, LLC situated in Hollywood, Florida and Quality Medical Research located in Nashville, Tennessee."
At how many distinct locations is this medical trial being administered?
"Patients are being recruited at Encore Medical Research. LLC situated in Hollywood, Florida, Quality Medical Research based in Nashville, Tennessee, and Encore Medical Research of Weston, LLC located in Weston, Michigan along with 6 additional sites."
What is the level of risk associated with Part 1A, Part 1B: GS-1427 Dose C for individuals?
"Our team at Power has evaluated the safety of Part 1A, Part 1B: GS-1427 Dose C to be a level 2 on our scale. This decision is based on the fact that this trial falls under Phase 2, indicating existing data supporting safety but lacking evidence for efficacy."
Share this study with friends
Copy Link
Messenger